PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN
PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.
Projectdetails
Introduction
Chronic pain (CP) is the most prevalent disease worldwide and is a major societal challenge. Different people with the same pain condition experience it differently. Irrespective of its origin, CP is maintained by altered connectivity between brain regions, which can be modulated towards normality by effective treatment.
Current Treatment Challenges
Several pharmacological and non-pharmacological strategies exist to treat pain, but 40% of individuals remain symptomatic despite treatment. Current treatment for CP is not personalized, being delivered in a standardized regimen irrespective of patients' brain network status, which partially justifies therapeutic refractoriness.
Non-Invasive Neuromodulation Techniques
Non-invasive neuromodulation (NIN) techniques such as repetitive transcranial magnetic stimulation (rTMS) are used in the long-term treatment of a wide spectrum of brain disorders as an alternative to medication-exclusive regimens. NIN can modulate altered connectivity towards normal patterns and relieve symptoms with minimal side effects, but to date its application has also been non-individualized, which equally impacts its therapeutic potential.
Proposed Study
I propose a comprehensive package of studies using measurements of local-to-global brain connectivity to individualize pain treatment. By probing different brain regions by single pulse-TMS and reading the subsequent brain oscillatory responses by electroencephalography, one can:
- Screen potential treatment targets
- Classify them according to their efficacy potential in a pre-treatment session
This will allow the identification of the best cortical region to be used as a treatment target by rTMS, thus providing a personalized choice of the ideal entry-spot to drive brain global connectivity towards normalized patterns for each patient.
Conclusion
With the development of local-to-general brain connectivity metrics guiding NIN treatment, PersoNINpain will provide an innovative and ground-breaking approach to transform the treatment of the world’s most impactful health condition - chronic pain.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.618.278 |
Totale projectbegroting | € 1.618.278 |
Tijdlijn
Startdatum | 1-8-2023 |
Einddatum | 31-7-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- AALBORG UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Uncovering the cortical cellular basis of specificity and chronicity of painThis project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief. | ERC Advanced... | € 2.468.700 | 2025 | Details |
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disordersThis project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders. | ERC Advanced... | € 2.424.481 | 2024 | Details |
Descending control of painDescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
MODular and EXpandable multi-locus Transcranial Magnetic StimulationDevelop an affordable, automated multi-locus TMS system to enhance brain stimulation efficiency and efficacy, improving treatment outcomes for various neurological disorders. | ERC Proof of... | € 150.000 | 2024 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Uncovering the cortical cellular basis of specificity and chronicity of pain
This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.
A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders
This project aims to transform chronic pain treatment by identifying transdiagnostic mechanisms and developing digital and virtual reality interventions to prevent chronicity and associated mental disorders.
Descending control of pain
DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.
MODular and EXpandable multi-locus Transcranial Magnetic Stimulation
Develop an affordable, automated multi-locus TMS system to enhance brain stimulation efficiency and efficacy, improving treatment outcomes for various neurological disorders.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Oro Movement AIDit project onderzoekt de haalbaarheid van AI en machine learning voor het ontwikkelen van een instrument dat chronische pijn bij patiënten effectief kan monitoren en analyseren. | Mkb-innovati... | € 20.000 | 2022 | Details |
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIESThe project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy. | EIC Pathfinder | € 2.999.840 | 2024 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
A synaptic mechanogenetic technology to repair brain connectivityDeveloping a mechanogenetic technology using magnetic nanoparticles to non-invasively regulate neural circuits for treating treatment-resistant brain disorders like stroke and epilepsy. | EIC Pathfinder | € 3.543.967 | 2023 | Details |
MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulationMETA-BRAIN aims to develop non-invasive, precise control of brain activity using magnetoelectric nanoarchitectures and ultrasonic technologies, enhancing treatment for neurological disorders. | EIC Pathfinder | € 2.987.655 | 2024 | Details |
Oro Movement AI
Dit project onderzoekt de haalbaarheid van AI en machine learning voor het ontwikkelen van een instrument dat chronische pijn bij patiënten effectief kan monitoren en analyseren.
LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIES
The project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.
A synaptic mechanogenetic technology to repair brain connectivity
Developing a mechanogenetic technology using magnetic nanoparticles to non-invasively regulate neural circuits for treating treatment-resistant brain disorders like stroke and epilepsy.
MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulation
META-BRAIN aims to develop non-invasive, precise control of brain activity using magnetoelectric nanoarchitectures and ultrasonic technologies, enhancing treatment for neurological disorders.